Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Beyfortus is a prescription monoclonal antibody containing nirsevimab-alip. It is used to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants born during or entering their first RSV season and in children up to 24 months who remain vulnerable to severe RSV disease through their second RSV season. A healthcare professional gives it by intramuscular injection.
read more about beyfortus ...Nirsevimab-alip targets the prefusion form of the RSV F protein. It binds a conserved site on that protein and blocks the structural changes RSV needs to fuse with human cell membranes and enter cells. This passive antibody protection lasts about five months after a recommended dose.
Beyfortus is used in newborns and infants born during or entering their first RSV season. It is also used in children up to 24 months who remain at increased risk for severe RSV disease through their second season. Safety and efficacy have not been established in children older than 24 months.
During the first RSV season, infants under 5 kg receive 50 mg and those weighing 5 kg or more receive 100 mg as one intramuscular injection. Children entering a second RSV season who remain at increased risk receive 200 mg as two 100 mg injections. Cardiac surgery with cardiopulmonary bypass can call for another dose after surgery.
Serious hypersensitivity reactions, including anaphylaxis, have been reported after Beyfortus. Reactions have included hives, breathing difficulty, bluish skin color, and reduced muscle tone. Intramuscular injection also requires caution in infants and children with thrombocytopenia, clotting disorders, or anticoagulant treatment due bleeding risk.
No. Beyfortus is a monoclonal antibody that gives passive protection against RSV rather than training the immune system through vaccination.
Clinical data in the prescribing information indicate that protection from a recommended dose extends through about five months.
Infants under 5 kg receive 50 mg, while infants weighing 5 kg or more receive 100 mg.
Yes. Beyfortus can be given with routine childhood vaccines using separate syringes and different injection sites.
BEYFORTUS (nirsevimab-alip) Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761328s019lbl.pdf. Date Accessed September 16, 2026.
DailyMed - BEYFORTUS (nirsevimab) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2f08fa60-f674-432d-801b-1f9514bd9b39. Date Accessed September 16, 2026.
Drug Trials Snapshots: BEYFORTUS. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-beyfortus. Date Accessed September 16, 2026.
FDA Approves New Drug to Prevent RSV in Babies and Toddlers. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-prevent-rsv-babies-and-toddlers. Date Accessed September 16, 2026.
Nirsevimab-alip. MedlinePlus. https://www.medlineplus.gov/druginfo/meds/a623033.html. Date Accessed September 16, 2026.